Side-by-side comparison of AI visibility scores, market position, and capabilities
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
US YC W24 interactive e-commerce email builder enabling in-email shopping (browse/buy) for Shopify merchants at 27% more revenue vs traditional emails; $700K seed competing with Klaviyo flows for AMP-powered in-inbox checkout conversion.
Zaymo is a United States-based interactive e-commerce email platform — backed by Y Combinator (W24) with $700,000 in seed funding from YC — providing Shopify merchants and e-commerce brands with an email builder that creates fully interactive emails where customers can browse product catalogs, select variants (size, color), add items to cart, and complete purchases directly within the email inbox without being redirected to the brand's website. Founded in 2022 and generating 27% more revenue than traditional email commerce approaches, Zaymo addresses the conversion friction of standard e-commerce emails where every product click requires a browser redirect that drops the majority of email recipients who were about to convert.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.